ArticleJournal of mood and anxiety disorders2026
Dose effect of bilateral transcranial magnetic stimulation for depression and anxiety in a real-world clinical setting.
Article in Journal of mood and anxiety disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcranial Magnetic Stimulation (TMS) is a non-invasive intervention for treatment-resistant depression (TRD). Comorbid anxiety is common in TRD patients. We examined the effect of single-dose versus high-dose bilateral TMS on depression and anxiety.
methodsSeventy-eight patients received 1 Hz right dorsolateral prefrontal cortex (DLPFC) stimulation combined with left single-dose or high-dose iTBS to the left DLPFC at a nonprofit clinic. Depression and anxiety symptoms were measured at baseline, after 10 and 20 sessions, and final (30-36) TMS sessions.
resultsBilateral TMS resulted in a significant decrease in depression (F(3,70)= 9.670, p < .001; 74.4% response, 47.7% remission) and anxiety (F(3,70)= 4.916, p = 0.004, 52.6% response, 39.7% remission). The high-dose group showed a faster reduction in depression (F(3,70)= 2.875, p = 0.042), but not anxiety symptoms. There was no dose difference at the final session.
conclusionBilateral TMS improved depression and anxiety symptoms with a quicker reduction in depression symptoms with higher dosing, which highlights an important clinical consideration to reduce visits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.